title: Psychopharmacogenetics--a challenge for pharmacotherapy in psychiatry.
abstract: Differences in response to treatment or the incidence of adverse drug effects are quite common in clinical psychopharmacotherapy. Although several factors may account for these discrepancies, there is increasing knowledge that genetic factors play a major role. The aim of pharmacogenetics, a new and rapidly growing field in research, is to elucidate the variability in drug response and metabolism due to hereditary differences. According to the hypotheses on the mechanisms of drug action, several mutations in genes coding for neurotransmitter receptors, degrading enzymes, transport proteins or enzymes of the drug metabolizing system (P-450 isoenzymes) have been identified and investigated in psychiatric disorders over the last years. Although some controversy exists among the results, many studies are supportive of the hypothesis that psychopharmacogenetics will be helpful in predicting an individual patient's drug response while minimising the rate of side effects.
authors.affiliation: Department of Psychiatry, Ludwig-Maximilians-University, Nussbaumstrasse 7 80336, Munich, Germany. bb@psy.med.uni-muenchen.de
authors.forename: B
authors.initials: B
authors.lastname: Bondy
authors.forename: P
authors.initials: P
authors.lastname: Zill
mesh_terms: D002746:Chlorpromazine / Q000009:adverse effects*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000235:genetics; D007703:Peptidyl-Dipeptidase A / Q000235:genetics; D017354:Point Mutation / Q000235:genetics; D011110:Polymorphism, Genetic / Q000235:genetics; D017981:Receptors, Neurotransmitter / Q000187:drug effects / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics
chemical_list: D017981:Receptors, Neurotransmitter; D007703:Peptidyl-Dipeptidase A; D002746:Chlorpromazine